Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of erlotinib versus carboplatin + vinorelbine in elderly patients with untreated advanced non-small cell lung cancer
2005-005827-32Phase 2Completed
- Sponsor
- Verein zur Förderung der Pneumologie am Krankenhaus Großhansdorf
- Start
- Mar 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Erlotinib with Carboplatin + vinorelbine (2 arms). Primary endpoint: Efficacy and safety of erlotinib versus carboplatin + vinorelbine. Started Mar 2006; status: completed.
02
Drugs
erlotinibcarboplatinvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-005827-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005827-32.